Can SPhotonix’s optical memory technology protect data better than today’s storage?
Updated
January 8, 2026 6:32 PM
SPhotonix's 5D Memory Crystals™. PHOTO: SPHOTONIX
SPhotonix, a young deep-tech startup, is working on something unexpected for the data storage world: tiny, glass-like crystals that can hold enormous amounts of information for extremely long periods of time. The company works where light and data meet, using photonics—the science of shaping and guiding light—to build optical components and explore a new form of memory called “5D optical storage”.
It’s based on research that began more than twenty years ago, when Professor Peter Kazansky showed that a small crystal could preserve data—from the human genome to the entire Wikipedia—essentially forever.
Their new US$4.5 million pre-seed round, led by Creator Fund and XTX Ventures, is meant to turn that science into real products. And the timing aligns with a growing problem: the world is generating far more digital data than current storage systems can handle. Most of it isn’t needed every day, but it can’t be thrown away either. This long-term, rarely accessed cold data is piling up faster than existing storage infrastructure can manage and maintaining giant warehouses of servers just to keep it all alive is becoming expensive and environmentally unsustainable.
This is the problem SPhotonix is stepping in to solve. They want to store huge amounts of information in a stable format that doesn’t degrade, doesn’t need electricity to preserve data and doesn’t require constant swapping of hardware. Instead of racks of spinning drives, the idea is a durable optical crystal storage system that could last for generations.
The company’s underlying technology—called FemtoEtch™—uses ultrafast lasers to engrave microscopic patterns inside fused silica. These precisely etched structures can function as high-performance optical components for fields like aerospace, microscopy and semiconductor manufacturing. But the same ultra-controlled process can also encode information in five dimensions within the crystal, transforming the material into a compact, long-lasting archive capable of holding massive amounts of information in a very small footprint.
The new funding allows SPhotonix to expand its engineering team, grow its R&D facility in Switzerland and prepare the technology for real-world deployment. Investors say the opportunity is significant: global data generation has more than doubled in recent years and traditional storage systems—drives, disks, tapes—weren’t designed for the scale or longevity modern data demands.
While the company has been gaining attention in research circles (and even made an appearance in the latest Mission Impossible film), its next step is all about practical adoption. If the technology reaches commercial viability, it could offer an alternative to the energy-hungry, short-lived storage hardware that underpins much of today’s digital infrastructure.
As digital information continues to multiply, preserving it safely and sustainably is becoming one of the biggest challenges in modern computing. SPhotonix’s work points toward a future where long-lasting, low-maintenance optical data storage becomes a practical alternative to today’s fragile systems. It offers a more resilient way to preserve knowledge for the decades ahead.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.